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Abstract
The role of microRNAs in small-cell lung carcinoma (SCLC) is largely unknown. miR-34a is known as a p53 regulated tumor
suppressor microRNA in many cancer types. However, its therapeutic implication has never been studied in SCLC, a cancer
type with frequent dysfunction of p53. We investigated the expression of a panel of 7 microRNAs (miR-21, miR-29b, miR-
34a/b/c, miR-155, and let-7a) in 31 SCLC tumors, 14 SCLC cell lines, and 26 NSCLC cell lines. We observed significantly lower
miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines. The expression of the 7 microRNAs was
unrelated to SCLC patients’ clinical characteristics and was neither prognostic in term of overall survival or progression-free
survival nor predictive of treatment response. Overexpression or downregulation of miR-34a did not influence SCLC cell
viability. The expression of these 7 microRNAs also did not predict in vitro sensitivity to cisplatin or etoposide in SCLC cell
lines. Overexpression or downregulation of miR-34a did not influence sensitivity to cisplatin or etoposide in SCLC cell lines.
In contrast to downregulation of the miR-34a target genes cMET and Axl by overexpression of miR-34a in NSCLC cell lines,
the intrinsic expression of cMET and Axl was low in SCLC cell lines and was not influenced by overexpression of miR-34a.
Our results suggest that the expression of the 7 selected microRNAs are not prognostic in SCLC patients, and miR-34a is
unrelated to the malignant behavior of SCLC cells and is unlikely to be a therapeutic target.
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Introduction
Small cell lung cancer (SCLC) accounts for about 10–20% of
lung cancer cases and is notorious for its aggressiveness and poor
survival rate [1,2]. Despite moderate progress achieved in the past
two decades, the survival rate of SCLC patients is still very poor
[2,3]. Partially due to the lack of adequate molecular biomarkers
to guide treatment of SCLC, the clinical results of molecular
targeted therapies such as imatinib, gefitinib, bcl-2 inhibitors, and
mTOR inhibitors in the treatment of SCLC patients are
disappointing [4].
MicroRNA expression correlates with biological characteristics
of cancer, such as cell differentiation, aggressiveness, invasion,
angiogenesis, and metastatic behavior [5,6,7]. For example, the
miR-34 family members, miR-34a, miR-34b, and miR-34c, are
direct transcriptional targets of p53 and their expression induces
cell cycle arrest in cancer cell lines [8]. miR-29b acts as a tumor
suppressor microRNA through restoration of a normal DNA
methylation pattern [9]. Clinically, microRNA profiling has been
shown to aid in the diagnosis of cancer as well as prediction of
prognosis and treatment response [6,10]. The roles of microRNAs
in cancer biology and prognosis prediction in non-small cell lung
cancer (NSCLC) have been widely studied. Increased miR-34a
was associated with fewer relapses in a small retrospective study of
resected NSCLC patients [11]. Overexpression of let-7a, possibly
through suppression of the RAS oncogene [12], was shown to be
related to increased overall survival in NSCLC patients [13], and
was also among the protective prognostic factors preventing
recurrence in surgically resected NSCLC [14]. Overexpression of
‘‘oncomirs’’ miR-21 and miR-155 was shown to be related to
decreased overall survival in NSCLC patients [13,15]. There is
only scant data on the role of microRNA expression in SCLC, and
the function of several well-documented cancer-related micro-
RNAs in other cancer types has never been addressed in SCLC.
For instance, although SCLC is characterized by frequent p53
dysfunction [16], the role of miR-34a, a p53 regulated tumor
suppressor microRNA [8,17], has never been studied in SCLC.
We recently demonstrated, by using a real-time polymerase
chain reaction (PCR) -based plateform, that expression profiles of
a panel of seven cancer-associated microRNAs (miR-21, miR-29b,
miR-34a/b/c, miR-155, and let-7a) are neither predictive nor
prognostic in NSCLC patients receiving platinum-based adjuvant
chemotherapy [18]. However, in resected pancreatic cancer using
the same panel of microRNAs, we showed that low expression of
miR-21 was associated with increased survival following adjuvant
treatment in two independent cohorts of pancreatic ductal
adenocarcinoma patients [19], suggesting that expression of
microRNAs and their prognostic and predictive implications are
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likely to be tumor specific. In the current study, we explored the
role of microRNAs for the prediction of both prognosis and
treatment outcome in SCLC using patient samples and SCLC cell
lines. We further studied how expression of miR-34a affects the
malignant behavior of SCLC cells.
Results
microRNA expression in SCLC tumors and lung cancer
cell lines
Table 1 summarizes the main patients’ characteristics, and
Table S1 depicts microRNA expression in relation to clinical
variables. Trends were observed in favor of higher let-7a
expression in women and in younger patients (p = 0.07 and 0.13
respectively, by Wilcoxon Rank-Sum test). No significant corre-
lations were observed between expression of microRNAs and
clinical characteristics. We compared expression of the 7
microRNAs between SCLC cell lines and NSCLC cell lines.
Lower expression of miR-21, miR-29b, and miR-34a was found in
SCLC cell lines than in NSCLC cell lines (p,0.001 for all three
microRNAs, Figure S1), which is in agreement with a previous
report [20]. We further performed in situ hybridization of miR-34b
in a SCLC tumor specimen and observed cytoplasmic expression
of miR-34b and nuclear expression of nucleolar RNA U6 as
expected (Figure S2).
microRNA expression is not correlated with survival of
SCLC patients
The median overall survival and progression-free survival of this
study cohort were 49.1 and 35.7 weeks, respectively. As expected,
longer overall survival was observed in SCLC patients who had
limited disease and patients who achieved complete response after
treatment (Table 1 and Table S2). Among the 7 microRNAs
studied, there was no survival difference between patients with
high and low microRNA expression, defined by the median
expression of each microRNA in tumor specimens (Table 2). This
was true in both limited and extensive disease patients (Table S3).
p53 protein expression is unrelated to miR-34a/b/c
expression in SCLC tumors
As miR-34a, miR-34b, and miR-34c are direct transcriptional
targets of p53 [8] and bcl-2 is a target of miR-34a[21], we
explored whether p53 expression affects expression of miR-34a/
b/c and whether bcl-2 expression is related to miR-34a. Using
specimens from the same study cohort, Dingemans et al
demonstrated that protein expression of p53 is unrelated to
survival of SCLC patients and is unrelated to protein expression of
bcl-2 as well [22]. We observed that protein expression of p53 in
SCLC tumors was unrelated to expression of miR-34a, miR-34b,
and miR-34c (Figure S3A, B, and C). Additionally, expression of
miR-34a was unrelated to expression of bcl-2 in SCLC tumors
(Figure S3D).
miR-34a expression is not related to viability of SCLC in
vitro
To explore the role of microRNA expression in the malignant
behavior of SCLC, we focused on miR-34a because miR-34a was
reported to be a prognostic survival marker [11] and to be one of
the few candidates for microRNA replacement therapy in NSCLC
[23,24]. We over-expressed or down-regulated miR-34a in SCLC
cells. Using a Cy3-labeled miR precursor or inhibitor to evaluate
the transfection efficacy, we found that 24 hours after transfection,
the transfection efficacy of miR-precursor or inhibitor in NCI-H82
SCLC cells was nearly 100% (Figure S4). High transfection
efficacy was also observed in NCI-H146, NCI-N592, GLC4,
A549, and NCI-H1299 cells (data not shown). We observed higher
mature miR-34a expression in cells transfected with miR-34a
precursor and lower mature miR-34a expression in cells
transfected with miR-34a inhibitor as compared to cells transfect-
ed with control precursor and inhibitor, respectively (Figure 1A).
Whereas overexpression of miR-34a induces G1 arrest in several
cancer cell lines[8], G1 arrest was not observed in NCI-H82
SCLC cell transfected with miR-34a precursor (Figure 1B).
Downregulation of miR-34a in NCI-H146 cells, which expressed
higher level of miR-34a in comparison with the median expression
Table 1. Patient characteristics and survival.
Characteristics No. OS p-value
Total no. of patients 31
Age, median(yr) (range) 63 (38–78)
# median 16 49.1 0.687
. median 15 48.1
Gender male 25 52.0 0.253
female 6 43.1
Disease extent Limited 18 52.7 0.007
Extensive 13 40.4
Chemotherapy CEE 20 51.5 0.132
CEV/PE 11 40.4
Response Complete response 8 66.4 ,0.001
Non-complete response 23 43.1
Radiotherapy Yes 13 58.3 0.052
No 18 36.6
OS: median overall survival (weeks). CEE, cyclophosphamide-epirubicin-
etoposide. CEV/PE, cyclophosphamide-epirubicin-vincristine alternated with
carboplatin-etoposide.
doi:10.1371/journal.pone.0021300.t001
Table 2. microRNA expression and survival analysis in SCLC
patients.
OS p-value PFS p-value
mir21 high 51.5 0.67 38.4 0.75
low 46.9 33.9
mir29b high 49.1 029 35.7 0.74
low 46.4 32.7
mir34a high 49.1 0.52 34.9 0.52
low 46.9 36.1
mir34b high 52.0 0.50 34.9 0.35
low 46.4 36.1
mir34c high 52.7 0.71 42.0 0.67
low 40.4 33.9
mir155 high 51.6 0.74 35.7 0.77
low 46.9 34.9
let-7a high 45.0 0.70 30.1 0.95
low 53.1 36.1
Cut off values were the median of each microRNA expression OS: median
overall survival (weeks), PFS: median progression-free survival (weeks).
doi:10.1371/journal.pone.0021300.t002
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level of the 14 SCLC cell lines (Table S4), and in NCI-N592 cells,
which expressed lower level of miR-34a, did not influence viability
of SCLC cells (Figure 1C and D). In contrast to the generally
accepted tumor suppressor effect of miR-34a, overexpression of
miR-34a in NCI-82 cells failed to attenuate cell growth (Figure 1E),
whereas attenuation of cell growth was observed in NCI-H1299
NSCLC cells (Figure S5), as demonstrated in a previous report
[23]. Unlike Wiggins et al. who demonstrated that repetitive
transfection and long-term incubation of miR-34a decreases NCI-
H226 NSCLC cancer cell viability [23], we failed to observe the
effect of repetitive transfection of miR-34a on decreasing the cell
viability in NCI-N592 cells (Figure 1F).
microRNA expression does not influence drug sensitivity
of SCLC cells
We first tested the correlation between microRNA expression
and sensitivity of the 14 SCLC cell lines to cisplatin and etoposide.
Not surprisingly, the sensitivity of SCLC cells to etoposide
correlates with the sensitivity to cisplatin (correlation coeffi-
cient = 0.74, p = 0.004). We observed that the expression of the
7 microRNAs was not associated with chemosensitivity of SCLC
cells to either agent (Table 3).
We next evaluated whether overexpression or downregulation
of miR-34a in SCLC cells would influence chemotherapy
sensitivity, as miR-34a expression was reported to be related to
chemotherapy resistance in a prostate cancer cell line [25]. NCI-
H82 cells, which carry a silent TP53 mutation (Table S4) were
transfected with control miR precursor, miR-34a precursor,
control miR inhibitor and miR-34a inhibitor, and subsequently
treated with cisplatin or etoposide. IC50 values upon cisplatin
treatment were 0.960.02 mM, 1.1960.3 mM, 0.8360.15 mM, and
0.7960.13 mM, respectively (p = 0.1 by one-way ANOVA)
(Figure 2A and B). The IC50 values upon etoposide treatment
were 0.2860.05 mM, 0.3160.04 mM, 0.5460.40 mM, and
0.5860.07 mM, respectively (p = 0.24) (Figure 2C and D). For
GLC4 cells, which carry K132E mutation in the TP53 gene
(Table S4), the IC50 values upon cisplatin treatment were
3.0360.87 mM, 2.5660.85 mM, 1.8760.30 mM, and
1.9260.61 mM, respectively (p = 0.14) (Figure S6A); the IC50
values upon etoposide treatment were 0.1960.03 mM,
0.2860.01 mM, 0.2060.03 mM, and 0.1960.06 mM, respectively
(p = 0.08) (Figure S6B). In summary, transient overexpression or
downregulation of miR-34a in SCLC cells did not affect the
sensitivity to cisplatin or etoposide, regardless of the TP53 status.
Expression of miR-34a target genes differ among cancer
cell lines
We evaluated the expression of selected miR-34a target-genes in
SCLC and NSCLC cell lines. Genes selected were MET[8],
MAP2K1[26], BCL2[21], and AXL[27]. We observed an inverse
correlation between miR-34a and c-MET but not bcl-2 expression
in 5 SCLC cell lines (Figure S7A and B). Despite relatively lower
miR-34a expression in SCLC cell lines (Figure S1), we did not
observe comparatively higher c-MET expression in SCLC cell
lines than in NSCLC cell lines (Figure S7A). We observed however
a decreased protein expression of cMET in A549 and NCI-H1299
NSCLC cell lines transfected with miR-34a precursor (Figure 3A).
Since cMET expression in NCI-H82 was undetectable, ectopic
expression of miR-34a or control precursors had no effect on
cMET expression, as expected. A decrease of bcl-2 protein
expression was observed in NCI-N592 cells transfected with miR-
34a precursor (Figure 3A). As only the MAP2K1 but not the
MAP2K2 gene is the target of miR-34a, we did not detect reduced
protein expression of MEK1/2 in cells transfected with miR-34a
precursor; this is presumably due to redundant roles of MAP2K1
and 2. Transfection of miR-34a precursor downregulated mRNA
expression of the AXL gene in A549 and NCI-H1299 NSCLC
cells by more than 70% (change of delta Ct by more than 1.7),
whereas the mRNA expression of the AXL gene in NCI-H82 and
NCI-N592 SCLC cells was too low to be detected by real-time
PCR assay (Figure 3B). In summary, we demonstrated that ectopic
expression of miR-34a could down-regulate miR-34a target-genes
in cells expressing the targets.
Discussion
Here we showed the expression of 7 known cancer-associated
microRNAs in SCLC tumors and cell lines as well as in NSCLC
cell lines. We observed that the expression of these microRNAs
was unrelated to clinical characteristics and outcome of SCLC
patients. Expression of these microRNAs was unrelated to the
sensitivity of SCLC cells to cisplatin or etoposide. Moreover,
overexpression or downregulation of miR-34a did not influence
SCLC cell viability or sensitivity to cisplatin and etoposide. We
further observed that the expression of miR-34a target genes may
differ among SCLC and NSCLC cell lines.
Although microRNAs have been widely studied in several
cancer types, there are only a few publications addressing the role
of microRNA in the malignant behavior of SCLC [20,28,29,30].
Miko et al. compared microRNA expression between SCLC cell
lines and tumor-free lung tissue from patients with chronic
obstructive pulmonary disease [28]. Du et al. compared the
microRNA expression pattern between 9 SCLC and 7 NSCLC
cell lines, and one mesothelioma cell line [20], and Guo et al.
compared a SCLC cell line, NCI-H69, with its doxorubicin-
resistant sub-line [30]. Ranade et al. reported the only study using
SCLC tumor specimens [29]; 16 microRNAs were studied for
survival analysis in 25 patients, and miR-92a-2* was identified as a
potential poor prognostic marker.
Although expression of the 7 microRNAs in our study was
evaluated in many cancer types in vitro, in vivo, and in tumor
specimens, they have not been evaluated before in relation to
patient survival in SCLC. Although our study is retrospective and
the patient cohort is small, this is by far the largest SCLC patient
cohort and collection of SCLC cell lines investigating microRNA
expression in this tumor type. In line with our previous report, a
posthoc analysis of a large prospective randomized trial in NSCLC
[18], the expression of the 7 microRNAs was not prognostic nor
did they correlate to treatment outcome in SCLC patients. We
cannot exclude the possibility that microRNAs other than the 7
microRNAs presented here may be important for SCLC, and
therefore further studies may be warranted in SCLC to evaluate
the prognostic value of microRNAs not included in this study.
miR-34a is a widely studied tumor suppressor microRNA that
mediates apoptosis, cell cycle arrest, inhibition of proliferation,
senescence, and inhibition of invasion and migration in various
cancer types (review by Hermeking et al. [31]). The tumor
suppressor effect of miR-34a on cancer cells, however, may be
tumor type specific; whereas miR-34a down-regulates growth of
IMR-90 fibroblast[8] as well as several NSCLC cell lines[23], Li et
al. showed that overexpression of miR-34a does neither affect cell
proliferation, cell cycle distribution, nor apoptosis in a hepatocel-
lular carcinoma cell line [32], and Pang et al. demonstrated that
overexpression of miR-34a has no effect on proliferation of
cervical cancer cell lines Hela and SiHa as well as choriocarci-
noma cell line JAR [33]. miR-34a is a direct transcriptional target
of p53 [8], and mutations of the TP53 gene have been found in
MicroRNA in SCLC
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Figure 1. Ectopic overexpression or downregulation of miR34a in SCLC cell lines by microRNA precursor or inhibitor. (A) miR-34a
expression in NCI-N592 cells and NCI-H82 cells transfected with miR-34a precursor or inhibitor. The delta-delta Ct value was calibrated to the delta Ct value
of miR34a in cells transfected with control miR precursor or inhibitor, respectively. (B) Cell cycle distribution of NCI-H82 cell transfected with control miR
precursor, miR-34a precursor, control miR inhibitor, and miR-34a inhibitor. (C and D) Cell growth assay of NCI-H146 (C) and NCI-N592 (D) cells transfected
with miR-34a inhibitor or control miR inhibitor. (E) Cell growth assay of NCI-H82 cells transfected with miR-34a precursor or control miR precursor. (F) Cell
viability of NCI-N592 cells after repetitive transfection of control miR precursor or miR-34a precursor. Cells were counted and transfected again every three
days. Error bars indicate standard deviation. p-values were calculated according to cell viability 5 days after transfection with the exception of microRNA
precursor in NCI-N592 cell, which was calculated according to the number of cells counted 9 days after the first transfection.
doi:10.1371/journal.pone.0021300.g001
MicroRNA in SCLC
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more than 75% of SCLC specimens [16]. A trend favoring lower
expression of miR-34a in SCLC cell lines compared to tumor-free
lung tissue has been observed previously [28]. In agreement with
our finding that ectopic miR-34a expression did not down-regulate
cell growth or induce G1 arrest, miR-34a expression did not
correlate with disease status (Table S1) and progression (Table 2)
of the SCLC patients. Intriguingly, all the SCLC cell lines tested in
this study expressed low level of cMET and Axl, two miR-34a
target genes. It is plausible that the growth suppression effect of
miR-34a may be tissue- and disease-specific, dictated possibly by
the level of intrinsic miR-34a target-gene expression in which cells
Table 3. microRNA expression and chemosensitivity to
etoposide or cisplatin in SCLC cell lines.
Etoposide Cisplatin
CC p-value CC p-value
miR-21 0.17 0.56 0.05 0.86
miR-29b 0.41 0.14 0.19 0.51
miR-34a 0.09 0.76 20.06 0.84
miR-34b 0.15 0.62 0.00 0.99
miR-34c 0.12 0.67 20.09 0.77
miR-155 0.13 0.66 20.33 0.25
let-7a 0.45 0.10 0.41 0.14
CC: correlation coefficient by Spearman method.
doi:10.1371/journal.pone.0021300.t003
Figure 2. Growth inhibition assay of NCI-H82 cells treated with (A and B) cisplatin and (C and D) etoposide. Cells were transfected with
the indicated oligonucleotides. Error bars indicate standard deviation of assays in triplicate.
doi:10.1371/journal.pone.0021300.g002
Figure 3. Expression of miR-34a target genes in SCLC and
NSCLC cancer cell lines. (A) protein expression of miR-34a targets in
cancer cell lines tranfected with control precursor (C) or miR-34a
precursor (M). (B) mRNA expression of the AXL gene in cancer cells
transfected with control precursor or miR-34a precursor. RNA was
collected 24 hr after transfection. The expression of the gene in NCI-
H82 and NCI-N592 cells were undetectable (UD).
doi:10.1371/journal.pone.0021300.g003
MicroRNA in SCLC
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with low levels of miR-34a target-gene expression, such as SCLC
cells, may render miR-34a functionally impotent.
In conclusion, the expression of 7 cancer-associated microRNAs
did not correlate to clinical outcomes of SCLC patients. miR-34a
expression was also not related to malignant behavior of SCLC
cancer cells and is thus unlikely to be a candidate therapeutic
target for this disease.
Materials and Methods
Patients and ethics statement
Thirty-one formalin fixed, paraffin-embedded (FFPE) tumor
samples from patients who were included in a phase III trial of the
North-Holland Oncology group [22] were obtained from the VU
University Medical Center, Amsterdam, Netherlands, upon
approval of the Institutional Review Board [22]. Written informed
consents were obtained from all participants.
Cell lines
A panel of 14 SCLC and 26 NSCLC cell lines were studied and
are listed in the Materials S1. All cancer cell lines were maintained
in RPMI-1640, supplemented with 10% fetal bovine serum (FBS),
with the exception of NCI-H792 which was maintained in DMEM
supplemented with 10% FBS. The TP53 gene mutation in cell
lines was determined by searching the p53 web site (http://p53.
free.fr/), the IARC TP53 Database (http://www-p53.iarc.fr/),
and the COSMIC database (http://www.sanger.ac.uk/genetics/
CGP/cosmic/).
RNA extraction
Total RNA was extracted from FFPE samples using the
RecoverAll Total Nucleic Acid Isolation kit (Ambion, Austin,
TX) and total RNA from cell lines was extracted with Trizol
reagent (Invitrogen, Carlsbad, CA), in accordance with the
manufacturer’s instructions.
Quantitative Real-Time PCR (qRT-PCR)
Expression of mature miRNAs, including miR-21, miR-29b,
miR-34a/b/c, miR-155, and let-7a, was evaluated by qRT-PCR
analysis as described previously [18]. RNU6B snRNA was used as
an endogenous control. Each microRNA assay was performed in
triplicate. Expression of microRNAs was reported as delta Ct
value (Ct value of RNU6B – Ct value of target microRNA). We
defined the groups of tumors or cells with high or low expression
based on the median expression value of each microRNA.
Expression of AXL gene was performed by using Taqman gene
expression assay (Applied Biosystems) and was reported as delta Ct
value. GAPDH gene was used as endogeneous control.
Transfection of microRNA precursor or inhibitors
miR-34a precursor and inhibitor as well as Cy3-labeled control
miR precursor and inhibitor were purchased from Ambion.
Transfection of miR-precursor or inhibitor was carried out using
siPORTTM NeoFXTM Transfection Agent (Ambion) following
manufacturer’s recommendation at a final oligonucleotide con-
centration of 30 nM.
Cell growth analysis
To determine the effect of transfection on cell growth, 5,000–
10,000 cells transfected with the indicated microRNA precursor or
inhibitor were plated in 96-well plates. Cell growth was
determined by CellTiter 96 AQueousOne Solution Cell Prolifer-
ation Assay (Promega Corp. Madison, WI) every 24 hours for 5
successive days. Results were presented as the optical density (OD
value) absorbance at 490 nm.
Repetitive transfectin of N592 cell
100,000 NCI-N592 SCLC cells were plated into 24-well plates
and transfected with miR-34a precursor or control precursor.
Cells were harvested, counted, and transfected again with the
respective miRNAs every 72 hours.
Growth inhibition assays
Cisplatin and etoposide were obtained from Sigma-Aldrich (St.
Louis, MI). 10,000 cells were seeded into 96-well flat-bottomed
plates, transfected with indicated precursor or inhibitor micro-
RNAs, cultured for 24 hours before the addition of various
concentrations of cisplatin and etoposide, and incubated for an
additional 72-hour. The cytotoxic effects of cisplatin and etoposide
were determined by CellTiter 96 AQueousOne Solution Cell
Proliferation Assay. Experiments were performed in triplicate. The
percentage of cell viability was determined by dividing the
absorbance values of the treated cells by those of the untreated
cells, and the concentration of cisplatin or etoposide resulting in
50% growth inhibition (IC50) was determined.
Immunohistochemistry study
Immunohistochemistry study of p53 and bcl-2 in SCLC tumors
were performed and reported previously [22].
Western blot
NCI-N592 and A549 cells transfected with miR-34a precursor or
control precursor were incubated for 48 hours. Cells were
harvested, lysates were prepared, and Western blot was performed
as described previously [34]. Antibodies were obtained from Sigma-
Aldrich (actin), Santa Cruz Biotechnology Inc (c-MET), Cell
Signaling Technology (MEK1/2), and Dako (bcl-2). The intensities
of c-MET and bcl-2 were assessed using GeneTools software
(SynGene), normalized by the intensity of actin, and calibrated to
the expression level in A549 and NCI-H146 cell, respectively.
Cell cycle analysis by flow cytometry
48 hours after transfection, cells were collected, washed with
cold PBS, fixed with cold 70% ethanol in PBS for at least
24 hours, and labeled with propidium iodide before counting cells.
After staining, cells were counted on FACScalibur using the
Cellquest Pro software (Becton Dickinson and Company, Frankin
Lakes, NJ). Cell cycle fractions were analyzed using the Modfit
v3.0 software.
In situ hybridization of microRNAs
In situ hybridization of miR-34b was performed as described
previously [18]. Nucleolar RNA U6 was used as positive control.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0
(SPSS, Chicago, IL). Survival was calculated using the Kaplan-
Meier method. The comparison of survival between different
groups was determined by the log-rank test. The differences in
microRNA expression between groups were analyzed by the
Wilcoxon Rank-Sum test. The correlation between drug sensitivity
and microRNA expression was analyzed by Spearman rank
correlation. Comparison of drug sensitivity of cells transfected with
various oligonucleotides was carried out by one-way analysis of
variances (one-way ANOVA). All p-values were two-sides and p-
values less than 0.05 were regarded significant.
MicroRNA in SCLC
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Supporting Information
Figure S1 Expression of microRNAs in SCLC versus in
NSCLC cell lines. A delta Ct value of 215 indicates that the
expression of the microRNA in the cell is too low to be detected.
(TIF)
Figure S2 in situ hybridization of microRNAs in a SCLC
tumor. Nucleolar RNA U6 and miR-34b were detected using a
biotinyl tyramide-based system with Vector NovaRed as a
substrate (brown). Specimens for scramble negative control and
miR-34b were co-stained with Mayer’s hematoxylin (blue).
(TIF)
Figure S3 Correlation of expression of p53 and (A) miR-
34a, (B)miR-34b, and (C) miR-34c, and (D) correlation of
expression of miR-34a and bcl-2. Expression of p53 and bcl-
2 were presented as percentage of stained cells by immunohisto-
chemistry. Correlation coefficient (r) and p-value were determined
by Spearman method.
(TIF)
Figure S4 NCI-H82 cell transfected with (A) Cy3-labeled
microRNA inhibitor and (B) Cy3-labeled microRNA
precursor.
(TIF)
Figure S5 Cell growth assay of NCI-H1299 NSCLC cells
transfected with miR-34a or control precursor. Error bars
refer to standard deviations.
(TIF)
Figure S6 Growth inhibition assay of the GLC4 cells
treated with (A) cisplatin and (B) etoposide. Cells were
transfected with the indicated oligonucleotides. Error bars indicate
standard deviation of assays in triplicate.
(TIF)
Figure S7 Protein expression of c-MET and bcl-2 in 5
SCLC and 3 NSCLC cell lines. (B) Correlation between
miR-34a and c-MET expression as well as bcl-2 in 5
SCLC cell lines.
(TIF)
Table S1 MicroRNAs and clinical covariables.
(DOC)
Table S2 Effect of clinical covariables on progression-
free survival (PFS).
(DOC)
Table S3 Effect of microRNA expression on progres-
sion-free survival (PFS, weeks) in SCLC patients strat-
ified by limited disease or extensive disease.
(DOC)
Table S4 TP53 status and miR-34a expression in SCLC
cell lines.
(DOC)
Materials S1 Cancer cell lines.
(DOC)
Author Contributions
Conceived and designed the experiments: JHL JV GG. Performed the
experiments: JHL JV AMCD DMV TP. Analyzed the data: JHL YW GG.
Contributed reagents/materials/analysis tools: AMCD. Wrote the paper:
JHL JV DMV YW GG.
References
1. Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366:
1385–1396.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. (2006)
Changing epidemiology of small-cell lung cancer in the United States over the
last 30 years: analysis of the surveillance, epidemiologic, and end results
database. J Clin Oncol 24: 4539–4544.
3. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC (2007) Small cell
lung cancer: have we made any progress over the last 25 years? Oncologist 12:
1096–1104.
4. Hurwitz JL, McCoy F, Scullin P, Fennell DA (2009) New advances in the
second-line treatment of small cell lung cancer. Oncologist 14: 986–994.
5. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev
Cancer 6: 857–866.
6. Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge
impact. J Clin Oncol 27: 5848–5856.
7. Cho WC (2010) MicroRNAs in cancer - from research to therapy. Biochim
Biophys Acta 1805: 209–217.
8. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA
component of the p53 tumour suppressor network. Nature 447: 1130–1134.
9. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-
29 family reverts aberrant methylation in lung cancer by targeting
DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104:
15805–15810.
10. Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis,
prognosis and targets for therapy. Int J Biochem Cell Biol 42: 1273–1281.
11. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, et al. (2009) miR-34a
as a prognostic marker of relapse in surgically resected non-small-cell lung
cancer. Carcinogenesis 30: 1903–1909.
12. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is
regulated by the let-7 microRNA family. Cell 120: 635–647.
13. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006)
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
Cancer Cell 9: 189–198.
14. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, et al. (2008) MicroRNA
signature predicts survival and relapse in lung cancer. Cancer Cell 13:
48–57.
15. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, et al.
(2008) Prognostic value of mature microRNA-21 and microRNA-205
overexpression in non-small cell lung cancer by quantitative real-time RT-
PCR. Clin Chem 54: 1696–1704.
16. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. (2002) The IARC
TP53 database: new online mutation analysis and recommendations to users.
Hum Mutat 19: 607–614.
17. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al.
(2007) Transactivation of miR-34a by p53 broadly influences gene expression
and promotes apoptosis. Mol Cell 26: 745–752.
18. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, et al. (2010)
MicroRNA expression and clinical outcomes in patients treated with adjuvant
chemotherapy after complete resection of non-small cell lung carcinoma. Cancer
Res 70: 8288–8298.
19. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, et al. (2010)
Identification of microRNA-21 as a biomarker for chemoresistance and clinical
outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One
5: e10630.
20. Du L, Schageman JJ, Irnov, Girard L, Hammond SM, et al. (2010) MicroRNA
expression distinguishes SCLC from NSCLC lung tumor cells and suggests a
possible pathological relationship between SCLCs and NSCLCs. J Exp Clin
Cancer Res 29: 75.
21. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34
inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
22. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, et al.
(1999) Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta
genes predicts survival and response to chemotherapy in patients with small cell
lung cancer. Clin Cancer Res 5: 2048–2058.
23. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010)
Development of a lung cancer therapeutic based on the tumor suppressor
microRNA-34. Cancer Res 70: 5923–5930.
24. Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement
therapy. Cancer Res 70: 7027–7030.
25. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of
miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
Biochem Biophys Res Commun 377: 114–119.
26. Ichimura A, Ruike Y, Terasawa K, Shimizu K, Tsujimoto G (2010) MicroRNA-
34a inhibits cell proliferation by repressing mitogen-activated protein kinase
kinase 1 during megakaryocytic differentiation of K562 cells. Mol Pharmacol 77:
1016–1024.
27. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, et al. (2011)
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-
199a/b in solid cancer. Oncogene online publication 14 February 2011; doi:
10.1038/onc.2011.13.
MicroRNA in SCLC
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21300
28. Miko E, Czimmerer Z, Csanky E, Boros G, Buslig J, et al. (2009) Differentially
expressed microRNAs in small cell lung cancer. Exp Lung Res 35: 646–664.
29. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, et al. (2010)
MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic
for survival in patients with small cell lung cancer. J Thorac Oncol 5:
1273–1278.
30. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, et al. (2010) Gene expression profiling of
drug-resistant small cell lung cancer cells by combining microRNA and cDNA
expression analysis. Eur J Cancer 46: 1692–1702.
31. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death
Differ 17: 193–199.
32. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and
invasion by downregulation of c-Met expression in human hepatocellular
carcinoma cells. Cancer Lett 275: 44–53.
33. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, et al. (2010) MicroRNA-34a
suppresses invasion through downregulation of Notch1 and Jagged1 in cervical
carcinoma and choriocarcinoma cells. Carcinogenesis 31: 1037–1044.
34. Harada T, Lopez-Chavez A, Xi L, Raffeld M, Wang Y, et al. (2011)
Characterization of epidermal growth factor receptor mutations in non-small-
cell lung cancer patients of African-American ancestry. Oncogene advance
online publication 30: 1744–1752.
MicroRNA in SCLC
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21300
